These include the extremely low yield of CD34+ cells that can be collected for gene modification relative to those routinely achieved in non-FA patients; the extreme sensitivity of FA cells to ex vivo culture [37, 92]. The gene discussed is CD34; the disease is Friedreich ataxia.